RLYB Stock Summary and Trading Ideas (Rallybio | NASDAQ:RLYB)

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Rallybio trades on the NASDAQ stock market under the symbol RLYB.

As of October 2, 2026, RLYB stock price climbed to $17.08 with 7,741 million shares trading.

RLYB has a beta of 0.45, meaning it tends to be less sensitive to market movements. RLYB has a correlation of 0.00 to the broad based SPY ETF.

RLYB has a market cap of $90.74 million. This is considered a Micro Cap stock.

In the last 3 years, RLYB traded as high as $36.80 and as low as $1.76.

The top ETF exchange traded funds that RLYB belongs to (by Net Assets): VTI, VXF, IWC, DFAS, DFMC.

RLYB has outperformed the market in the last year with a return of +317.3%, while the SPY ETF gained +16.1%. In the last 3 month period, RLYB beat the market returning +8.0%, while SPY returned +3.6%. However, in the most recent 2 weeks RLYB has underperformed the stock market by returning -0.6%, while SPY returned +1.0%.

RLYB support price is $16.35 and resistance is $17.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RLYB shares will trade within this expected range on the day.